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Effect of cessation of GH treatment on
cognition during transition phase in Prader-
Willi syndrome: results of a 2-year crossover
GH trial
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Abstract
Background: Patients with Prader-Willi syndrome (PWS) have a cognitive impairment. Growth hormone (GH)
treatment during childhood improves cognitive functioning, while cognition deteriorates in GH-untreated children
with PWS. Cessation of GH treatment at attainment of adult height (AH) might deteriorate their GH-induced
improved cognition, while continuation might benefit them. We, therefore, investigated the effects of placebo
versus GH administration on cognition in young adults with PWS who were GH-treated for many years during
childhood and had attained AH.
Method: Two-year, randomized, double-blind, placebo-controlled cross-over study in 25 young adults with PWS.
Cross-over intervention with placebo and GH (0.67 mg/m2/day), both during 1 year.
Results: Total (TIQ), verbal (VIQ) and performance IQ (PIQ) did not deteriorate during 1 year of placebo, compared
to GH treatment (p > 0.322). Young adults with a lower TIQ had significantly more loss of TIQ points during placebo
versus GH, in particular VIQ decreased more in those with a lower VIQ. The effect of placebo versus GH on TIQ, VIQ
and PIQ was not different for gender or genotype.
Conclusions: Compared to GH treatment, 1 year of placebo did not deteriorate cognitive functioning of GH-
treated young adults with PWS who have attained AH. However, patients with a lower cognitive functioning had
more loss in IQ points during placebo versus GH treatment. The reassuring finding that 1 year of placebo does not
deteriorate cognitive functioning does, however, not exclude a gradual deterioration of cognitive functioning on
the long term.
Trial registration: ISRCTN24648386, NTR1038, Dutch Trial Register, www.trialregister.nl. Registered 16 August 2007.
Keywords: Prader-Willi syndrome, Growth hormone treatment, Cognition, Young adults
Background
Prader-Willi Syndrome (PWS) is a neurogenetic disorder
resulting from the lack of expression of the PWS region
on the paternally derived chromosome 15, caused by pa-
ternal deletion, maternal uniparental disomy (mUPD),
imprinting center defect (ICD) or balanced translocation
[1]. PWS is characterized by a number of symptoms,
such as muscular hypotonia, short stature, abnormal
body composition with high fat mass and low lean body
mass, severe hyperphagia, behavioral problems and
cognitive impairment [1–3].
MRI studies in PWS suggested that lower cortical
complexity partially underlies cognitive impairment and
developmental delay [4], with structural brain abnormal-
ities and different neurodevelopmental patterns between
children with a deletion and an mUPD [5]. Certain cogni-
tive skills improved significantly during GH treatment,
while GH-untreated children with PWS showed a deteri-
oration of cognitive functioning [6, 7]. Children with an
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mUPD started off with lower visuospatial skills, but
showed a significant improvement during 4 years of
growth hormone (GH), resulting into a similar cognitive
functioning in all genotypes [6].
GH treatment has also positive effects on body compos-
ition, bone mineral density, psychomotor development,
adaptive functioning, linear growth and adult height (AH)
[6–11]. As a result, GH treatment has substantially chan-
ged the phenotype of children with PWS [8, 11], but when
they attain AH, they have to stop GH treatment because
most do not fulfill the criteria of adult GH deficiency.
There are no studies about cognition after stop of GH
treatment in this new generation of PWS patients. In un-
treated adults with PWS, lower IGF-I levels were corre-
lated with poorer intellectual skills [12], which might
suggest that discontinuation of GH treatment, which
decreases IGF-I, could be disadvantageous.
Given the positive effects of GH and IGF-I levels on
cognition in children with PWS, we hypothesized that the
cognition in young adults with PWS would deteriorate after
cessation of GH treatment compared to the continuation of
GH administration. We, therefore, investigated the effects of
placebo versus GH on cognition in young adults with PWS
who had attained AH, in a 2-year, randomized, double-
blind, placebo-controlled cross-over study.
Methods
Subjects
Inclusion criteria of the present study were (1) genetic-
ally confirmed diagnosis of PWS; (2) GH treatment
during childhood for at least 2 years and being on GH at
time of inclusion; and (3) AH attainment, defined as a
height velocity less than 0.5 cm per 6 months and
complete epiphyseal fusion. Exclusion criteria were (1)
use of medication to reduce weight; (2) non-cooperative
behavior; or (3) inability to perform cognitive tests. Due
to the last exclusion criterion, 2 patients could not par-
ticipate; 1 due to poor cognitive skills and a severe hear-
ing impairment, and with an IQ of 58 who refused to
speak in the hospital. From June 2008 to January 2014,
33 young adults fulfilled the inclusion criteria. Two did
not want to continue GH-injections and 3 parents re-
fused participation due to too large burden of hospital
visits. Twenty-eight young adults (8 boys, 20 girls) with
PWS aged 14.1–20.2 years were included in the GH/pla-
cebo study. One participant died due to gastric rupture
3 months after start while receiving placebo. Twenty-five
young adults completed the present study.
During childhood, the standard GH dose was 1 mg/
m2/day. In the present study during transition from
childhood into adulthood, GH dose was set lower at
a fixed dose of 0.67 mg/m2/day (≈0.023 mg/kg/day).
We did neither titrate on serum IGF-I levels nor on
body composition. Twelve (48%) young adults used
sex steroid replacement therapy, 7 (28%) thyroid hor-
mone supplementation, 2 (8%) modafinil and 1 (4%)
risperidone and citalopram. All patients were on a
strict diet and an exercise program.
Design
Two-year, randomized, double-blind, placebo-controlled,
cross-over study investigating the effects of 1 year pla-
cebo versus 1 year GH on cognitive functioning. The
duration per phase was 1 year in order to prevent retest-
ing phenomenon. A clinically relevant deterioration of cog-
nitive functioning was arbitrarily defined as a decrease of 5
IQ points, taking into account the significant improvement
of IQ during 4 years GH treatment in children with PWS
[6]. Young adults were stratified according to gender and
BMI (below/above 25 kg/m2) and then randomly and
blindly assigned to receive 1 year of subcutaneous injections
once daily at bedtime of either 0.67 mg/m2/day GH
(Genotropin®, 5 mg/ml, Pfizer) or 1 year of identical appear-
ing placebo (placebo, Pfizer), after which they crossed-over
to the alternative treatment for another year. An independ-
ent statistician generated the random allocation sequence.
Investigators were blinded for the allocation. An independ-
ent physician monitored the safety during the study. During
the entire study period, unblinding was not necessary.
Measurements
Patients were 3-monthly seen by the PWS-team of the
Dutch Growth Research Foundation in collaboration
with pediatric endocrinologists and pediatricians. At
each visit, the injection dose was adjusted to the calcu-
lated body surface area. In addition, patients visited the
Sophia’s Children Hospital every 6 months and at base-
line, 12 and 24 months the following data were obtained:
cognitive functioning, anthropometric measurements,
fasting blood levels of IGF-I, and (severe) adverse events.
All cognitive measurements were performed by a
psychologist experienced in testing young adults with
PWS. The 11 recommended subscales of Wechsler
Adult Intelligence Scale 3rd Edition (WAIS-III) were
used to assess total IQ (TIQ) in patients over 16 years of
age [13]. Verbal IQ (VIQ) subtests were Vocabulary, Simi-
larities, Arithmetic, Digit Span, Information and Compre-
hension. Performance IQ (PIQ) subtests were Picture
Completion, Coding, Block design, Matrix Reasoning and
Picture Arrangement. The 10 recommended subscales of
Wechsler Intelligence Scale for Children 3rd Edition
(WISC-III) were used to assess TIQ in 4 patients younger
than 16 years [14]. VIQ subtests were Information, Simi-
larities, Arithmetic, Vocabulary and Comprehension. PIQ
subtests were Picture Completion, Coding, Picture
Arrangement, Block Design and Visual Puzzles. It was re-
ported that WISC IQ and WAIS IQ are comparable in
16 year old young adults [15]. In both tests, scores on all
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subtests were expressed as standard deviation scores,
based on Dutch population data for the same age [13, 14].
Standard subtest scores ranged from 1 (−3 SDS) to 19 (+3
SDS), with a mean of 10 (0 SDS).
Standing height was measured with a calibrated
Harpenden stadiometer, weight was determined on a cal-
ibrated scale (ServoBalance KA-20-150S) and BMI was
calculated. Height, weight and BMI were expressed as
SDS, adjusted for age and sex [16, 17]. SDS values were
calculated with GrowthAnalyser 4.0.
Assays
Blood samples were collected after an overnight fast and
measured in one laboratory. IGF-I was measured using an
immunometric technique on Immulite 1000 (LKGF1,
Siemens Medical Solutions Diagnostics) with an interassay
variation <7.5%. Serum levels of IGF-I were expressed as
SDS, adjusting for age and gender [18, 19].
Statistics
Statistical analysis was performed with SPSS version 23.0.
Calculation of sample size indicated that 22 subjects were
required for a power of >80% with a significance level of
0.05. As data were not normally distributed, nonparamet-
ric tests were used and data expressed as median (inter-
quartile range (IQR)), unless otherwise described.
Statistical analysis appropriate for cross-over trials were
used, taking into account any carry-over or treatment-
period effect, calculated by Wilcoxon Signed Rank test
and Mann Whitney U tests, but these were not found.
Correlations between effect of GH treatment and other
parameters were assessed using Spearman’s rho. Differ-
ences were considered significant if p-value was <0.05.
Study approval
Written informed consent was obtained from patients
and parents. The study protocol was approved by the
Medical Ethics Committee of Erasmus University
Medical Center, Rotterdam, and registered at Dutch
Trial Register (www.trialregister.nl NTR1038).
Results
Baseline characteristics
Median age of the 25 young adults with PWS (7 boys,
18 girls) with cognitive functioning tests was 17.8 (15.7
to 18.5) years and BMI was +1.1 (−0.8 to +1.7) SDS
(Table 1). Nine (36%) patients had a deletion, 13 (52%)
an mUPD, 2 (8%) an ICD and 1 (4%) a translocation. At
baseline (adult height (AH)), both treatment arms had
similar characteristics. During childhood, GH treatment
was started at a median (IQR) age of 8.8 (6.3 to 10.1)
years and patients were treated for 8.6 (7.0 to 10.5) years
until AH.
Cognitive Functioning at AH
Median total IQ (TIQ) at AH was 62 (56 to 73)
points, with a non-significantly higher verbal IQ
(VIQ) of 65 (57 to 72) points than performance IQ
(PIQ) of 60 (54 to 72) points (p = 0.157) (Table 1).
Placebo
TIQ, VIQ and PIQ had not changed after 1 year of pla-
cebo (p = 0.422, p = 0.220 and p = 0.488) (Fig. 1). The
young adults had similar scores on the 11 subtests be-
fore and after 1 year of placebo (Table 2).
Associations during placebo
After 1 year of placebo, young adults scored lowest on
subtest Coding (−2.7 SDS) and highest on the subtests
Similarities, Information and Picture Arrangement
(median score −1.7 SDS). After 1 year of placebo, there
was no difference in TIQ, VIQ or PIQ between boys and
girls (p > 0.166) or between patients with a deletion and
mUPD+ ICD (p > 0.138). The IGF-I SDS during placebo
was not associated with TIQ, VIQ or PIQ (p > 0.602).
Placebo versus GH administration
Table 2 and Fig. 1 show the effects of 1 year of placebo
versus 1 year of GH administration on cognition. Com-
pared with GH treatment, placebo did not deteriorate
TIQ, VIQ or PIQ (p > 0.322). The difference between
placebo and GH administration was strongest in the
subtest Block Design, as patients scored 0.3 SDS worse
during placebo (median score placebo −2.0 SDS, GH ad-
ministration −1.66 SDS, p = 0.075), but the difference
did not reach significance. The young adults had similar
scores on the other 10 different subtests during placebo
and GH administration (all p > 0.123).
The effect of placebo versus GH administration on TIQ,
VIQ or PIQ was neither different between boys and girls
(p > 0.418), nor between young adults with a deletion ver-
sus mUPD + ICD (p > 0.138). Young adults with a lower
TIQ had more loss in TIQ points during placebo versus
GH (ρ = −0.407, p = 0.043), indicating that if the TIQ is 1
point lower, the difference in TIQ points during placebo
versus GH increases with 0.407 points. In particular those
with a lower VIQ had more decrease in VIQ points during
placebo (ρ = −0.467, p = 0.021). The loss in TIQ or VIQ
points was not associated with IGF-I SDS during GH or
placebo, or age of start GH treatment. In order to further
investigate this association, the 8 patients in lowest TIQ
tertile were compared with those in the highest tertile.
During both GH treatment and placebo, TIQ, VIQ and
PIQ were significantly lower in the lowest tertile com-
pared to the highest tertile (all p = 0.036). There was no
difference in age, BMI, FM%, LBM, IGF-I during placebo
or GH, age at start GH treatment, duration GH treatment
and GH peak during stimulation test.
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Limited cognitive functioning is commonly defined as
an IQ score below 70 points [20]. Seven (28%) young
adults had a VIQ and 9 (36%) a PIQ higher than 70
points, during both placebo and GH treatment.
Associations with GH peak during stimulation test
After the 2-year study, twenty-three young adults under-
went an arginine-GHRH test. Only 3 (13%) had a GH
peak below the BMI-dependent cut-off [21]. There was
no significant influence of the GH peak on the effects of
placebo versus GH administration on TIQ, VIQ or PIQ
(p > 0.604).
Discussion
This is the first 2-year, randomized, double-blind,
placebo-controlled GH study in young adults with PWS
who were treated with GH during childhood until AH,
investigating the effects of cessation of GH (placebo)
versus GH administration on cognitive functioning. Our
data show that, compared to GH administration, 1 year
of placebo did not deteriorate TIQ, VIQ or PIQ in the
total group of young adults with PWS. However, patients
with a lower cognitive functioning had more loss in IQ
points during placebo versus GH treatment.
In this study, we investigated whether the GH-induced
improvement in cognitive functioning during childhood
would be lost during 1 year of placebo. Our results are
reassuring, as there was no significant deterioration in
TIQ, VIQ or PIQ after 1 year of placebo in young adults
with PWS. If IQ had deteriorated after cessation of GH
treatment, this would have suggested that sustained acti-
vation with GH was required to retain the improved
cognitive functioning achieved during childhood. We
found, however, that IQ remained similar after 1 year of
Table 1 Baseline characteristics of total group and per treatment schedule
PWS (n = 25) Placebo/GH (n = 12) GH / Placebo (n = 13) p*
Boys/girls (n) 7/18 3/9 4/9
Genetic subtype
- Deletion 9 2 7
- mUPD 13 8 5
- ICD/translocation 3 9 1
Age (yrs) 17.8 (15.7 to 18.5) 17.2 (14.9 to 19.4) 17.8 (16.9 to 18.0) 0.852
Adult height (SDS) −1.7 (−2.2 to–1.0) −1.7 (−2.4 to–1.1) −1.8 (−2.0 to −0.9) 0.852
BMI for age (SDS) 1.1 (−0.8 to 1.7) 1.3 (−0.4 to 1.7) 1.1 (−0.8 to 2.0) 0.936
BMI for age PWS (SDS) −1.1 (−2.2 to −0.6) −1.2 (−2.2 to −0.6) −1.1 (−2.3 to −0.5) 0.689
Age at start GH treatment (yrs) 8.8 (6.3 to 10.1) 8.1 (5.8 to 9.8) 8.8 (6.9 to 11.2) 0.376
Duration of GH treatment (yrs) 8.6 (7.0 to 10.5) 8.7 (7.2 to 11.4) 8.3 (6.5 to 10.5) 0.650
IGF-I (SDS) 2.1 (1.7 to 3.0) 1.7 (1.1 to 3.0) 2.2 (2.0 to 3.0) 0.051
FM% 38.6 (32.3 to 44.9) 39.0 (32.4 to 45.6) 37.3 (30.5 to 44.9) 0.810
Lean body mass (kg) 36.5 (30.6 to 41.5) 35.0 (29.6 to 43.9) 37.0 (33.2 to 40.2) 0.611
Total IQ 62 (56 to 73) 60 (54 to 63) 67 (57 to 78) 0.095
Verbal IQ 65 (57 to 72) 66 (60 to 72) 65 (55 to 74) 0.713
- Vocabulary −2.3 (−2.8 to −1.7) −2.3 (−2.8 to −1.8) −2.0 (−2.8 to −1.4) 0.464
- Similarities −2.0 (−2.5 to −1.0) −2.0 (−2.7 to −1.5) −1.7 (−2.5 to −0.8) 0.382
- Arithmetic −2.0 (−2.0 to −1.7) −2.0 (−2.3 to −1.6) −2.0 (−2.0 to −1.6) 0.635
- Digit Span −2.0 (−2.3 to −2.0) −2.0 (−2.0 to −1.2) −2.3 (−2.4 to −1.9) 0.129
- Information −1.7 (−2.0 to −1.3) −1.7 (−1.8 to −1.3) −1.8 (−2.0 to −1.3) 0.792
- Comprehension −2.0 (−2.6 to −1.5) −2.2 (−2.7 to −1.6) −2.0 (−2.4 to −1.2) 0.792
Performance IQ 60 (54 to 72) 59 (54 to 67) 66 (52 to 74) 0.635
- Picture Completion −2.5 (−3.0 to −1.5) −2.5 (−2.8 to −1.7) −2.5 (−3.0 to −1.3) 0.792
- Coding −3.0 (−3.0 to −2.3) −3.0 (−3.0 to −2.6) −2.9 (−3.0 to −1.6) 0.428
- Block design −2.2 (−2.2 to −1.3) −2.0 (−3.0 to −1.5) −1.5 (−1.9 to −0.8) 0.034
- Matrix Reasoning −2.3 (−2.3 to −1.3) −2.0 (−2.3 to −1.7) −2.0 (−2.3 to −1.0) 0.786
- Picture Arrangement −2.7 (−2.7 to −1.5) −2.3 (−2.8 to −1.8) −1.7 (−2.0 to −1.4) 0.082
Data expressed as median (IQR). *Comparison between two treatment schedules
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placebo, which might indicate that GH treatment during
childhood has long-lasting effects. To our knowledge,
there are no studies investigating the effects of cessation
of GH treatment on cognition after AH attainment.
The scores of the subtest Block Design, however,
tended to deteriorate after 1 year of placebo compared
to GH treatment, but the decrease of 0.3 SDS was not
significant. An RCT in children with PWS showed that
2 years of GH treatment did not significantly improve
Block Design scores compared to baseline. Only after
4 years of GH treatment, Block Design scores had in-
creased approximately 0.3 SDS, which was significantly
higher than at baseline [6]. Thus, our finding that TIQ
did not change during 1 year of placebo compared to
GH treatment, while Block Design scores tended to de-
teriorate, does not exclude that stop of GH treatment
for many years could result in a deterioration of cogni-
tive functioning on the long term. It might be that 1 year
of placebo is too short to show a significant decrease in
cognitive functioning.
There are no other studies on cognitive functioning in
young adults with PWS who received long-term GH
during childhood. Only one study investigated the effects
of GH treatment versus placebo on cognitive functioning
in adults with PWS, but these PWS adults were older
and GH-untreated at inclusion. They demonstrated that
the subtest Block Design and Coding improved during
GH treatment and benefits were more pronounced in
patients who were GH-treated for the longest time [22].
In untreated adults with PWS, lower IGF-I levels were
correlated with poorer intellectual skills [12], which is in
line with the beneficial effects of GH treatment, which
increases IGF-I. We, however, neither found a correl-
ation between IGF-I SDS during placebo and IQ, nor be-
tween IGF-I SDS during GH or placebo and the loss in
Table 2 Cognitive function, body composition and IGF-I SDS of PWS adolescents at different stages in the study
Treatment schedule p-value
Placebo/GH (n = 12) GH/Placebo (n = 13)
After 1 year placebo After 1 year GH After 1 year GH After 1 year placebo
Total IQ 61 (55 to 69) 62 (58 to 69) 69 (60 to 73) 70 (57 to 80) 0.832
Verbal IQ 62 (55 to 66) 65 (57 to 70) 66 (57 to 75) 67 (55 to 76) 0.486
- Vocabulary −2.3 (−2.7 to −2.0) −2.2 (−2.9 to −2.0) −2.3 (−3.0 to −1.3) −2.0 (−2.7 to −1.5) 0.650
- Similarities −1.8 (−2.2 to −1.7) −1.7 (−2.3 to −1.1) −1.3 (−2.3 to −1.0) −1.3 (−2.3 to −1.0) 0.943
- Arithmetic −2.0 (−2.2 to −2.0) −2.0 (−2.0 to −1.7) −2.0 (−2.0 to −1.7) −2.0 (−2.0 to −1.8) 0.320
- Digit Span −2.2 (−2.8 to −1.7) −2.3 (−2.9 to −1.8) −2.0 (−2.3 to −1.8) −2.0 (−2.3 to −1.8) 0.793
- Information −1.7 (−2.6 to −1.7) −1.8 (−2.0 to −1.4) −1.7 (−2.0 to −1.1) −1.8 (−2.3 to −1.3) 0.154
- Comprehension −2.3 (−2.7 to −2.3) −2.2a (−2.6 to −2.0) −2.0 (−2.6 to −1.4) −2.0 (−2.6 to −1.4) 0.123
Performance IQ 59 (53 to 72) 57 (52 to 70) 67 (57 to 75) 69 (55 to 78) 0.322
- Picture Completion −2.2 (−2.9 to −1.7) −2.5 (−2.9 to −1.7) −1.7 (−2.8 to −0.8) −1.3 (−2.3 to −0.4) 0.130
- Coding −3.0 (−3.0 to −2.2) −2.7 (−3.0 to −2.3) −2.5 (−3.0 to −1.5) −2.3 (−3.0 to −1.5) 0.903
- Block design −2.0 (−2.2 to −1.4) −1.5a (−2.0 to −1.3) −1.7 (−1.8 to −1.2) −1.7 (−2.0 to −1.0) 0.075
- Matrix Reasoning −1.7 (−2.1 to −1.3) −2.3a (−2.3 to −1.7) −2.2 (−2.3 to −1.2) −2.2 (−2.3 to −1.3) 0.376
- Picture Arrangement −2.3 (−2.6 to −1.2) −2.0 (−2.3 to −1.4) −1.7 (−1.7 to −1.0) −1.3 (−2.0 to −1.0) 0.611
FM% 45.3 (38.2 to 48.3) 41.7 (30.6 to 50.6) 39.3a (33.2 to 49.8) 44.1 (38.4 to 52.3) 0.002
Lean body mass (kg) 32.3 (30.6 to 45.1) 34.6a (31.6 to 44.0) 35.1 (32.6 to 41.3) 36.7 (31.5 to 39.2) 0.008
IGF-I SDS −0.4 (−0.9 to −0.3) 2.1a (0.0 to 2.4) 1.8a (1.5 to 2.4) −0.7 (−1.7 to 0.3) <0.001
Data expressed in SDS; median with IQR. P-value of mean difference between placebo and GH administration, tested by Wilcoxon tests
awithin Placebo/GH or GH/placebo group; significantly different compared to placebo
Fig. 1 Cognitive functioning at baseline, after 1 year of GH treatment and
after 1 year of placebo. Total, performance and verbal IQ at baseline
(in light grey), after 1 year of placebo (in white) and after 1 year of GH
treatment (in dark grey). Boxes represent 1st and 3rd quartile, with median
in the middle. Whiskers indicate range. There are no significant differences
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IQ points. It might be that the beneficial effects of the
long-term GH treatment which our patients received
during childhood are not nullified during the short time
of placebo of 1 year.
In contrast to our current findings of unaltered cogni-
tive functioning after 1 year of placebo versus GH ad-
ministration, we found an impressive deterioration of
the body composition within this period [19]. This might
suggest that the beneficial effects on cognition of GH
treatment during childhood last into adulthood. The
exact mechanism how GH exerts its beneficial effects on
cognitive functioning is unknown. It has been suggested
that GH may directly affect its GH receptors which are
widespread throughout the brain, or through release of
IGF-I [23]. The neurotrophic effects of GH continue
during adulthood, and it has been proposed that the
age-related decline in GH secretion is involved in the
decreased neurogenesis in healthy elderly [23]. Amongst
them, those with higher IGF-I levels have better
cognitive functioning and lower rates of cognitive de-
cline [24, 25]. Besides, an RCT showed that GHRH ad-
ministration in healthy elderly and in adults with a mild
cognitive impairment had favorable effects on cognition
[26]. Like in other syndromes, ageing in PWS might
occur prematurely, and lower GH levels might be in-
volved in this, but data are very limited [27, 28]. In other
syndromes, like Down Syndrome, age-related diseases as
dementia with loss of function in multiple cognitive do-
mains are more prevalent and occur earlier [29]. A
deterioration in cognitive functioning over time is also
seen in patients with Alzheimer’s disease, and GH ad-
ministration reduced learning and memory deficits in
animals with this disease [23]. In adults with GH defi-
ciency, GH administration improved long-term and
working memory functions [30, 31]. Altogether, these re-
sults support the hypothesis that the GH-IGF-I axis is
involved in cognitive functioning [32]. How GH
treatment achieves its beneficial effects needs to be elu-
cidated, but it suggests that GH might have neuropro-
tective effects. Thus, continuation of GH treatment
might also benefit adults with PWS, while it cannot be
excluded that cessation of GH impairs cognitive func-
tioning on the long-term.
Although there was no deterioration in TIQ, VIQ or
PIQ during 1 year of placebo, we found that young
adults with a lower cognitive functioning lost more IQ
points during placebo versus GH treatment, indicating
more benefit from GH treatment. This is in line with
our previous finding that GH treatment was more bene-
ficial for children with PWS with lower cognitive func-
tioning [6]. In elderly and in patients with GH deficiency
or Alzheimer, there was a positive correlation between
IGF-I levels and cognitive functioning, while this was
not found in a healthy adult group [33]. The authors
postulate that IGF-I levels are not involved in cognition
in case of relatively good cognitive performance. This is
in line with our findings and suggests that patients with
poor cognitive skills are more vulnerable for loss of
function. The mechanism is, however, not clear.
Young adults with PWS in our study showed a moder-
ate cognitive impairment, with median IQ scores being
about 5 to 10 points higher than documented by other
studies, who reported IQ scores between 50 and 60 or
around 52 points in adults with PWS [22, 34]. These pa-
tients had not received GH treatment during childhood
[34]. An explanation for the higher IQ scores in our
groups might be that all our participants were treated
with GH treatment for many years during their child-
hood, which is a crucial period for maturation of the
brain. GH treatment during childhood prevents deterior-
ation of cognitive skills and improves cognition on the
longer term [6]. The patients in this study started GH
treatment relatively late at an age of 8.8 years, whereas
the children with PWS who are nowadays born start at
an earlier age. It can be assumed that GH effects on cog-
nition will be even larger in the future.
Besides the higher IQ scores than reported in the lit-
erature, we also found a very wide variation in IQ scores.
One patient had a PIQ of 100 during GH and subse-
quently 92 during placebo, which is exceptionally high
for an individual with PWS. Furthermore, the 3rd quar-
tile of TIQ, PIQ and VIQ was higher than the cut-off for
intellectual disability [20], meaning that more than 25%
of the young adults had an IQ above 70 points. On the
other hand, there was a patient who was not able to par-
ticipate in this part of the study, as she had poor cogni-
tive skills in addition to her hearing impairment.
Previously reported percentages of poor cognitive skills
in individuals with PWS were around 14% [34, 35], while
this was present in only 1 of 27 patients in our group.
Cognition after stop of GH treatment and the effects
of placebo versus GH administration on cognition were
not different between patients with a deletion and those
with an mUPD or ICD. It has been described that pa-
tients with an mUPD have better verbal skills than those
with a deletion [6, 35]. These patients were, however,
not treated with GH. During 4 years of GH treatment,
children with an mUPD showed a larger improvement
than children with a deletion, resulting in a similar Block
Design score as those with a deletion after 4 years of GH
treatment [6]. We now found no difference in cognition
between those with a deletion versus mUPD + ICD,
which suggests that long-term GH treatment during
childhood improved cognitive functioning, particularly
of those with mUPD + ICD.
The ethical dilemma of 1 year placebo injections in
mentally disabled young adults was extensively discussed
with patients’ caregivers. The high clinical relevance
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ensured them to vote for the strongest design, being a 2-
year cross-over study. It might be that 1 year placebo
was too short to demonstrate alteration in cognitive
functioning and that no GH treatment will lead to a de-
terioration on the longer term. It was, however, consid-
ered unethical to extend the placebo period beyond
1 year given the convincing positive effects of GH on
body composition. It might be that the effect of GH ver-
sus placebo on cognitive skills would have reached sig-
nificance if we could have studied a larger group. This
was, however, not feasible as PWS is a rare disorder.
Conclusion
In conclusion, this cross-over trial in young adults with
PWS who were treated for many years with GH during
childhood shows that compared to GH treatment, 1 year
of placebo did not deteriorate cognitive functioning.
However, patients with a lower cognitive functioning
had more loss in IQ points during placebo versus GH
treatment. The reassuring finding that 1 year of placebo
does not deteriorate cognitive functioning does, how-
ever, not exclude a gradual deterioration of cognitive
functioning on the long term.
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